Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Cuts Target Price to $120
BTIG Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $135
Goldman Sachs Maintains Neutral on IRhythm Technologies, Raises Price Target to $124
A Quick Look at Today's Ratings for IRhythm Technologies(IRTC.US), With a Forecast Between $130 to $145
IRhythm Technologies Price Target Raised to $145.00/Share From $111.00 by Truist Securities
Irhythm Technologies: Strong Financial Performance and Strategic Advantages Support Buy Rating
IRhythm Technologies Is Maintained at Equal-Weight by Wells Fargo
Oppenheimer Adjusts IRhythm Technologies Price Target to $130 From $120, Maintains Outperform Rating
A Quick Look at Today's Ratings for IRhythm Technologies(IRTC.US), With a Forecast Between $135 to $152
IRhythm Technologies Analyst Ratings
Morgan Stanley Raises Price Target on IRhythm Technologies to $130 From $95, Keeps Overweight Rating
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Dynavax (DVAX) and Irhythm Technologies (IRTC)
BTIG Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Irhythm Technologies (IRTC), Vir Biotechnology (VIR) and Biogen (BIIB)
Needham Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $125
Citi Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Cuts Target Price to $100
Oppenheimer Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $120
CCORF Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $152
Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating
Needham Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $112